RxDoctor Payments Data

Ismail Bekdash, MD

Interventional Cardiology · Fargo, NDNPI 1386814044

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,571 of the $6,494 with a category attached, or 70.4%. 8 manufacturers reported payments, led by Abbott at 44.5% of the total.

$6,494in general payments, 2019–2025

Across 57 payments — averaging $113.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Edwards Lifesciences$2K
  • Medtronic$684
  • AstraZeneca$266
  • Abiomed$150
  • Boston Scientific$145
  • plus $79 from 2 others

What the payments were for

  • Travel & lodging$4,57170%
  • Food & beverage$1,65726%
  • Education$2664%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$330,169
Medicare patients
975
Services billed
2,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$81,648
XareltoRivaroxaban44$35,462
Repatha SureclickEvolocumab20$16,734
BrilintaTicagrelor13$12,776
Enoxaparin Sodium41$3,515
Warfarin Sodium160$1,410
Metoprolol Succinate57$1,287
Rosuvastatin Calcium52$655
Lisinopril39$490
JantovenWarfarin Sodium74$478
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$392
Carvedilol39$342
Atorvastatin Calcium28$325
Losartan Potassium44$324
Amlodipine Besylate34$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$266$12,77613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →